Annual CFI
$5.60 B
+$4.13 B+281.20%
31 December 2023
Summary:
Novartis AG annual cash flow from investing activities is currently $5.60 billion, with the most recent change of +$4.13 billion (+281.20%) on 31 December 2023. During the last 3 years, it has risen by +$18.78 billion (+142.45%). NVS annual CFI is now at all-time high.NVS Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$374.00 M
+$2.83 B+88.34%
30 September 2024
Summary:
Novartis AG quarterly cash flow from investing activities is currently -$374.00 million, with the most recent change of +$2.83 billion (+88.34%) on 30 September 2024. Over the past year, it has increased by +$1.84 billion (+83.09%). NVS quarterly CFI is now -103.52% below its all-time high of $10.62 billion, reached on 31 March 2023.NVS Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$6.24 B
+$1.84 B+22.75%
30 September 2024
Summary:
Novartis AG TTM cash flow from investing activities is currently -$6.24 billion, with the most recent change of +$1.84 billion (+22.75%) on 30 September 2024. Over the past year, it has dropped by -$12.13 billion (-205.96%). NVS TTM CFI is now -146.92% below its all-time high of $13.30 billion, reached on 30 June 2023.NVS TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVS Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +281.2% | +83.1% | -206.0% |
| 3 y3 years | +142.4% | +69.6% | -573.9% |
| 5 y5 years | +200.1% | +89.0% | +16.6% |
NVS Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +142.4% | -103.5% | +96.8% | -146.9% | +22.8% |
| 5 y | 5 years | at high | +142.4% | -103.5% | +96.8% | -146.9% | +54.4% |
| alltime | all time | at high | +135.5% | -103.5% | +97.2% | -146.9% | +69.5% |
Novartis AG Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$374.00 M(-88.3%) | -$6.24 B(-22.8%) |
| June 2024 | - | -$3.21 B(+256.7%) | -$8.08 B(+36.4%) |
| Mar 2024 | - | -$899.00 M(-48.9%) | -$5.92 B(-205.9%) |
| Dec 2023 | $5.60 B(+281.2%) | -$1.76 B(-20.4%) | $5.60 B(-5.0%) |
| Sept 2023 | - | -$2.21 B(+110.1%) | $5.89 B(-55.7%) |
| June 2023 | - | -$1.05 B(-109.9%) | $13.30 B(+388.2%) |
| Mar 2023 | - | $10.62 B(-824.0%) | $2.72 B(+85.6%) |
| Dec 2022 | $1.47 B(-65.1%) | -$1.47 B(-128.2%) | $1.47 B(-80.4%) |
| Sept 2022 | - | $5.20 B(-144.7%) | $7.50 B(+602.1%) |
| June 2022 | - | -$11.63 B(-224.2%) | $1.07 B(-91.7%) |
| Mar 2022 | - | $9.37 B(+105.2%) | $12.79 B(+204.0%) |
| Dec 2021 | $4.21 B(-131.9%) | $4.56 B(-470.4%) | $4.21 B(-554.4%) |
| Sept 2021 | - | -$1.23 B(-1370.1%) | -$926.00 M(-46.8%) |
| June 2021 | - | $97.00 M(-87.6%) | -$1.74 B(-23.1%) |
| Mar 2021 | - | $780.00 M(-236.6%) | -$2.26 B(-82.8%) |
| Dec 2020 | -$13.18 B(+492.2%) | -$571.00 M(-72.1%) | -$13.18 B(+7.2%) |
| Sept 2020 | - | -$2.04 B(+381.2%) | -$12.29 B(-9.9%) |
| June 2020 | - | -$425.00 M(-95.8%) | -$13.65 B(-0.4%) |
| Mar 2020 | - | -$10.14 B(-3289.0%) | -$13.70 B(+515.2%) |
| Dec 2019 | -$2.23 B(-60.2%) | $318.00 M(-109.4%) | -$2.23 B(-70.2%) |
| Sept 2019 | - | -$3.40 B(+616.9%) | -$7.48 B(+50.6%) |
| June 2019 | - | -$474.00 M(-135.7%) | -$4.97 B(+2856.5%) |
| Mar 2019 | - | $1.33 B(-126.9%) | -$168.00 M(-97.0%) |
| Dec 2018 | -$5.59 B(+79.3%) | -$4.93 B(+457.0%) | -$5.59 B(+238.4%) |
| Sept 2018 | - | -$886.00 M(-120.5%) | -$1.65 B(+13.9%) |
| June 2018 | - | $4.33 B(-205.6%) | -$1.45 B(-76.3%) |
| Mar 2018 | - | -$4.09 B(+311.1%) | -$6.11 B(+96.0%) |
| Dec 2017 | -$3.12 B(-9.4%) | -$996.00 M(+45.4%) | -$3.12 B(-2.4%) |
| Sept 2017 | - | -$685.00 M(+103.3%) | -$3.20 B(-2.1%) |
| June 2017 | - | -$337.00 M(-69.4%) | -$3.26 B(-13.4%) |
| Mar 2017 | - | -$1.10 B(+2.6%) | -$3.77 B(+9.6%) |
| Dec 2016 | -$3.44 B(-68.1%) | -$1.07 B(+42.7%) | -$3.44 B(-15.2%) |
| Sept 2016 | - | -$752.00 M(-10.9%) | -$4.06 B(-0.0%) |
| June 2016 | - | -$844.00 M(+9.3%) | -$4.06 B(-18.8%) |
| Mar 2016 | - | -$772.00 M(-54.3%) | -$5.00 B(-53.6%) |
| Dec 2015 | -$10.78 B(-1324.1%) | -$1.69 B(+124.4%) | -$10.78 B(+7.7%) |
| Sept 2015 | - | -$753.00 M(-57.8%) | -$10.01 B(+8.8%) |
| June 2015 | - | -$1.78 B(-72.8%) | -$9.21 B(+8.3%) |
| Mar 2015 | - | -$6.56 B(+613.5%) | -$8.50 B(-1064.7%) |
| Dec 2014 | $881.00 M(-126.3%) | -$919.00 M(-1801.9%) | $881.00 M(-203.0%) |
| Sept 2014 | - | $54.00 M(-105.0%) | -$855.00 M(-48.6%) |
| June 2014 | - | -$1.08 B(-138.2%) | -$1.66 B(+35.7%) |
| Mar 2014 | - | $2.82 B(-206.3%) | -$1.23 B(-63.5%) |
| Dec 2013 | -$3.35 B | -$2.65 B(+252.6%) | -$3.35 B(+3.7%) |
| Sept 2013 | - | -$753.00 M(+17.7%) | -$3.23 B(-27.4%) |
| June 2013 | - | -$640.00 M(-192.0%) | -$4.45 B(-1.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | $696.00 M(-127.4%) | -$4.53 B(-20.1%) |
| Dec 2012 | -$5.67 B(+616.5%) | -$2.54 B(+28.7%) | -$5.67 B(+43.2%) |
| Sept 2012 | - | -$1.97 B(+172.6%) | -$3.96 B(+54.7%) |
| June 2012 | - | -$723.00 M(+62.5%) | -$2.56 B(+48.2%) |
| Mar 2012 | - | -$445.00 M(-46.0%) | -$1.73 B(+118.2%) |
| Dec 2011 | -$792.00 M(-95.0%) | -$824.00 M(+44.8%) | -$792.00 M(+42.7%) |
| Sept 2011 | - | -$569.00 M(-617.3%) | -$555.00 M(-94.8%) |
| June 2011 | - | $110.00 M(-77.6%) | -$10.65 B(-24.6%) |
| Mar 2011 | - | $491.00 M(-183.6%) | -$14.13 B(-10.3%) |
| Dec 2010 | -$15.76 B(+10.8%) | -$587.00 M(-94.5%) | -$15.76 B(-18.6%) |
| Sept 2010 | - | -$10.66 B(+216.3%) | -$19.36 B(+47.2%) |
| June 2010 | - | -$3.37 B(+196.7%) | -$13.15 B(+5.1%) |
| Mar 2010 | - | -$1.14 B(-72.9%) | -$12.51 B(-12.0%) |
| Dec 2009 | -$14.22 B(+37.2%) | -$4.19 B(-5.8%) | -$14.22 B(+21.0%) |
| Sept 2009 | - | -$4.45 B(+63.0%) | -$11.76 B(-42.5%) |
| June 2009 | - | -$2.73 B(-3.9%) | -$20.43 B(+22.7%) |
| Mar 2009 | - | -$2.84 B(+64.4%) | -$16.64 B(+60.5%) |
| Dec 2008 | -$10.37 B(+66.0%) | -$1.73 B(-86.8%) | -$10.37 B(+0.5%) |
| Sept 2008 | - | -$13.12 B(-1348.6%) | -$10.32 B(-4877.3%) |
| June 2008 | - | $1.05 B(-69.4%) | $216.00 M(-113.1%) |
| Mar 2008 | - | $3.43 B(-304.3%) | -$1.64 B(-73.7%) |
| Dec 2007 | -$6.24 B(-1.8%) | -$1.68 B(-35.0%) | -$6.24 B(+21.1%) |
| Sept 2007 | - | -$2.59 B(+220.3%) | -$5.16 B(+72.9%) |
| June 2007 | - | -$808.00 M(-30.8%) | -$2.98 B(-57.8%) |
| Mar 2007 | - | -$1.17 B(+96.5%) | -$7.08 B(+11.3%) |
| Dec 2006 | -$6.36 B(-11.3%) | -$594.00 M(+43.5%) | -$6.36 B(-5.9%) |
| Sept 2006 | - | -$414.00 M(-91.6%) | -$6.75 B(-30.2%) |
| June 2006 | - | -$4.90 B(+994.0%) | -$9.67 B(-3.5%) |
| Mar 2006 | - | -$448.00 M(-54.8%) | -$10.02 B(+39.8%) |
| Dec 2005 | -$7.17 B(+154.5%) | -$991.00 M(-70.3%) | -$7.17 B(+29.7%) |
| Sept 2005 | - | -$3.33 B(-36.5%) | -$5.53 B(+47.3%) |
| June 2005 | - | -$5.25 B(-318.4%) | -$3.75 B(-528.3%) |
| Mar 2005 | - | $2.40 B(+269.7%) | $876.00 M(-131.1%) |
| Dec 2004 | -$2.82 B(+128.8%) | $650.00 M(-141.7%) | -$2.82 B(-24.6%) |
| Sept 2004 | - | -$1.56 B(+151.1%) | -$3.73 B(+20.4%) |
| June 2004 | - | -$620.00 M(-51.9%) | -$3.10 B(+25.7%) |
| Mar 2004 | - | -$1.29 B(+381.0%) | -$2.47 B(+100.5%) |
| Dec 2003 | -$1.23 B(-57.0%) | -$268.00 M(-71.0%) | -$1.23 B(+27.8%) |
| Sept 2003 | - | -$925.00 M(-6707.1%) | -$963.00 M(+2434.2%) |
| June 2003 | - | $14.00 M(-126.9%) | -$38.00 M(-26.9%) |
| Mar 2003 | - | -$52.00 M | -$52.00 M |
| Dec 2002 | -$2.87 B(+3.4%) | - | - |
| Dec 2001 | -$2.77 B(+1968.7%) | - | - |
| Dec 2000 | -$134.00 M(-92.9%) | - | - |
| Dec 1999 | -$1.89 B(-32.1%) | - | - |
| Dec 1998 | -$2.79 B | - | - |
FAQ
- What is Novartis AG annual cash flow from investing activities?
- What is the all time high annual CFI for Novartis AG?
- What is Novartis AG annual CFI year-on-year change?
- What is Novartis AG quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Novartis AG?
- What is Novartis AG quarterly CFI year-on-year change?
- What is Novartis AG TTM cash flow from investing activities?
- What is the all time high TTM CFI for Novartis AG?
- What is Novartis AG TTM CFI year-on-year change?
What is Novartis AG annual cash flow from investing activities?
The current annual CFI of NVS is $5.60 B
What is the all time high annual CFI for Novartis AG?
Novartis AG all-time high annual cash flow from investing activities is $5.60 B
What is Novartis AG annual CFI year-on-year change?
Over the past year, NVS annual cash flow from investing activities has changed by +$4.13 B (+281.20%)
What is Novartis AG quarterly cash flow from investing activities?
The current quarterly CFI of NVS is -$374.00 M
What is the all time high quarterly CFI for Novartis AG?
Novartis AG all-time high quarterly cash flow from investing activities is $10.62 B
What is Novartis AG quarterly CFI year-on-year change?
Over the past year, NVS quarterly cash flow from investing activities has changed by +$1.84 B (+83.09%)
What is Novartis AG TTM cash flow from investing activities?
The current TTM CFI of NVS is -$6.24 B
What is the all time high TTM CFI for Novartis AG?
Novartis AG all-time high TTM cash flow from investing activities is $13.30 B
What is Novartis AG TTM CFI year-on-year change?
Over the past year, NVS TTM cash flow from investing activities has changed by -$12.13 B (-205.96%)